Drugs / Ciprofibrate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT00350038 | Feb 2005 → Aug 2007 | hyperlipidemia, hypertensive disorder | Sanofi | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT03662984 Comparator | Nov 2018 → Nov 2020 | acute insulin response, diastolic heart failure, glucose metabolism disease | Maastricht University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01480687 Comparator | May 2011 → Dec 2012 | hypertensive disorder, hypertriglyceridemia | Hospital Universitario Pedro Ernesto | Unknown | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ciprofibrate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01480687 ↗ |
| Known as | Ciprofibrato | ChEMBL registry synonym — accepted as the source's own label CHEMBL557555 ↗ |
| Known as | Modalim | ChEMBL registry synonym — accepted as the source's own label CHEMBL557555 ↗ |
| Known as | NSC-759617 | ChEMBL registry synonym — accepted as the source's own label CHEMBL557555 ↗ |
| Known as | WIN 35833 | ChEMBL registry synonym — accepted as the source's own label CHEMBL557555 ↗ |
| Modality | Small molecule | — CHEMBL557555 ↗ |
| Route | Oral | “take one pill of ciprofibrate 100mg, or placebo, once daily” NCT03662984 ↗ |
| Target | PPARA | “Ciprofibrate is a PPARα ligand” NCT03662984 ↗ |